St. Jude Children's Research Hospital

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1962-01-01

Employees: -

Market Cap: -

Website: http://www.stjude.org/

Clinical Trials

SCD Stem Cell Mobilization and Apheresis Using Motixafortide

Phase 1

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Motixafortide

First Posted Date: 2024-06-04

Last Posted Date: 2024-12-18

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 15

Registration Number: NCT06442761

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Cardiopulmonary Function and Cerebral Blood Flow in Hodgkin Lymphoma Survivors

Recruiting

Conditions: Hodgkin Lymphoma, Adult

Interventions: Device: Near Infrared Spectroscopy (NIRS)

First Posted Date: 2024-05-20

Last Posted Date: 2024-07-01

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 100

Registration Number: NCT06421987

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Remote Exercise Video Adaptations to Maximize Physical Activity in Childhood Cancer

Recruiting

Conditions: Survivorship
Childhood Cancer
Frailty

First Posted Date: 2024-05-13

Last Posted Date: 2024-08-02

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 20

Registration Number: NCT06411704

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

Phase 2

Not yet recruiting

Conditions: T-cell Lymphoma
T-cell Acute Lymphoblastic Leukemia
Mixed Phenotype Acute Leukemia

Interventions: Drug: Dexamethasone
Drug: Vincristine
Drug: Daunorubicin
Drug: Calaspargase pegol
Drug: Venetoclax
Drug: Bortezomib
Drug: Dasatinib
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Mercaptopurine
Drug: Nelarabine
Drug: Methotrexate
Drug: Thioguanine

First Posted Date: 2024-04-30

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 145

Registration Number: NCT06390319

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

School Readiness Intervention for Preschool Children With Sickle Cell Disease

Not Applicable

Recruiting

Conditions: Sickle Cell Disease

Interventions: Device: The adapted Kids in Transition to School Intervention
Device: Standard school resources

First Posted Date: 2024-04-16

Last Posted Date: 2024-12-13

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 36

Registration Number: NCT06367192

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

Phase 1

Recruiting

Conditions: ALL, Childhood
MDS
AML, Childhood
Hematologic Malignancy
Lymphoma

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: CD70-CAR T cell infusion (Autologous)
Drug: Mesna

First Posted Date: 2024-03-22

Last Posted Date: 2024-12-17

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT06326463

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Phase 4

Not yet recruiting

Conditions: Lymphoblastic Lymphoma
Mixed Phenotype Acute Leukemia
Acute Lymphoblastic Leukemia

Interventions: Drug: Dexamethasone
Drug: Vincristine
Drug: Daunorubicin
Drug: Intrathecal triple therapy (methotrexate + hydrocortisone + cytarabine)
Drug: Methotrexate
Drug: Cytarabine

First Posted Date: 2024-03-04

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 850

Registration Number: NCT06289673

Locations: 🇺🇸
United States, Tennessee St. Jude Children's Research Hospital, Memphis, Tennessee, United States

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Phase 1

Recruiting

Conditions: Non-rhabdomyosarcoma
Adipocytic Neoplasm
Liposarcoma

Interventions: Procedure: Surgical resection
Radiation: Proton beam radiation therapy
Drug: Pazopanib
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Selinexor

First Posted Date: 2024-02-02

Last Posted Date: 2024-04-03

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 139

Registration Number: NCT06239272

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Parents Reflecting On Hope During Hospice Through Photovoice

Recruiting

Conditions: Bereavement

First Posted Date: 2024-01-02

Last Posted Date: 2024-08-07

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 25

Registration Number: NCT06187636

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Phase 1

Recruiting

Conditions: Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Acute Leukemia of Ambiguous Lineage

Interventions: Drug: Revumenib
Drug: Venetoclax
Drug: Azacitidine
Drug: intrathecal (IT) chemotherapy
Drug: Cytarabine
Drug: Methotrexate

First Posted Date: 2023-12-20

Last Posted Date: 2024-12-16

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 24

Registration Number: NCT06177067

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy